Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spheramine in Advanced Parkinson's Disease
NCT00206687Phase 2Terminated
- Sponsor
- Bayer
- Start
- Jan 2003
- Primary completion
- May 2012
- Modality
- Cell Therapies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of Spheramine in Parkinson's disease (PD) (2 arms), sponsored by Bayer. Primary endpoint: Change in UPDRS Part III (Motor Score) in the defined medication state at 12 months. Started Jan 2003; status: terminated.
02
Drugs
Spheramine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00206687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00206687.